Oyster Park Development

Oyster Point Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. The company's lead product, Tyrvaya (varenicline solution) nasal spray, is the first and only nasal spray approved by the FDA for the treatment of the signs and symptoms of dry eye disease. Oyster Point utilizes a novel mechanism of action that activates the trigeminal parasympathetic pathway to stimulate natural tear film production. In early 2023, the company was acquired by Viatris to serve as the foundation for its new ophthalmology franchise.